DARE News and Press, Dare Bioscience Inc. From 05/16/22

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a virtual fireside chat during the H.C. Wainwr...

Dare Bioscience, Inc. (DARE) Q1 2022 Earnings Conference Call May 12, 2022, 16:30 PM ET Company Participants Sabrina Martucci Johnson - President and Chief Executive Officer John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Zegbah J...

Dare Bioscience press release (NASDAQ:DARE): Q1 GAAP EPS of -$0.10 beats by $0.04. $39.3 million in cash and cash equivalents at March 31, 2022 For further details see: Dare Bioscience GAAP EPS of -$0.10 beats by $0.04

$39.3 million in cash and cash equivalents at March 31, 2022 Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022 Organon exclusive global license agreement for XACIATO™ (clindamycin phosphate vaginal gel, 2%): Expected to close in ...

Supports research to define end-user preferences among U.S. women to inform the design of long-acting injectable hormonal contraception Daré is developing novel injectable formulations of etonogestrel designed to provide 6- or 12-month contraceptive protection SAN D...

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 12, 2022, to review its financi...

Vancouver, Kelowna, Delta, BC - April 28, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining and Cleantech. Today's stocks have been added to our lists of free stock...

SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Wom...

Daré Bioscience (NASDAQ:DARE) began a phase 1/2 trial of DARE-HRT1 to treat vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. The company said DARE-HRT1 is a novel intravaginal ring designed to deliver bio-identical 17β-estradiol and bio-iden...

Prior Phase 1 Study Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause Current Phase 1/2 Study will Collect Symptom Relief and Acceptability Data in Addition to Evaluating Pharm acokin etics over a Three-Mo...